Fabrication and Investigation of Luliconazole Based 2T-SLN Gel for the Amelioration of Vulvovaginal Candidiasis | Chapter 2 | Advanced Research in Biological Science Vol. 7

 This member primarily focuses on fabrication and review of luliconazole based 2T-SLN coagulate for the amelioration of vulvovaginal candidiasis. Vulvovaginal candidiasis (VVC), is an exceedingly accepted mucosal infection of the lower female generative tract, caused mainly by the various opportunistic fungus Candida albicans. A appendage of the normal human microbiota, C. albicans usually colonizes the vaginal lumen asymptomatically. Fungal resistance and infection frequency are major questions with the existing situation regimens for VVC, that compromises the therapeutic efficacy of antifungal cures and results in protracted situation and low patient compliance. The gist of the present research was the lie and investigation of 2 T- SLN (solid lipid nanoparticles) coagulate carrying luliconazole for the improvement of VVC. ‘2T’ symbolizes transvaginal and thermosensitive attributes of the present expression. The optimized SLNs allowed a particle size, polydispersity index and entanglement efficiency of 62.18 nm, 0.263 and 81.5% individually. To formulate the 2 T-gel, the definitive SLNs were loaded into Carbopol 971P-NF and Triethanolamine-located gel. The 2 T-SLN gel was raise to be surely spreadable and homogenous with mean extrudability (15 ± 0.4 g/cm2), viscosity (696.42 ± 2.34 Pa•s) and %drug content (93.24 ± 0.73%) principles. The pH of the prepared 2 T-SLN coagulate (4.5 ± 0.5) was in concordance with the vaginal pH (usual conditions). For in-vitro description of an optimized 2 T-SLN gel, the release movement and anticandidal activity were evaluated which offers a %cumulative drug release of 62 ± 0.5% in 72 h and 37.3 ± 1.5 mm district of inhibition in 48 h. The developed 2 T-SLN gel was found expected stable at range temperature for two months without some visible non-regularity, cracking, or breaking. It also exhibits a skin-companionable profile accompanying no noticeable symptoms of erythema or oedema. Finally, the current research serves as a new therapeutic outlook in assessing the activity of luliconazole for vaginal drug transfer using a 2 T-SLN coagulate system.

Author(s) Details:

Salma Firdaus,
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.

Nazia Hassan,
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.

Mohd. Aamir Mirza,
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.

Tabasum Ara,
Department of Pharmaceutical Sciences, University of Kashmir, J&K, India.

Hamed A. El-Serehy,
Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.

Fahad A. Al-Misned,
Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.

Zeenat Iqbal,
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.

Please see the link here: https://stm.bookpi.org/ARBS-V7/article/view/12895

Determining the Enhancement of Oral Bioavailability VIA Solid Lipid Nanoparticles of Anticancer Drug Dasatinib - An In-vitro Cytotoxicity and Pharmacokinetic Study | Chapter 14 | Current Aspects in Pharmaceutical Research and Development Vol. 2

 Dasatinib (DST) is a Biopharmaceutics Classification System Class II medication with a high permeability and very low solubility. DST's low water solubility and poor dissolution result in low bioavailability. As a result, restricted aqueous solubility represents a bottleneck for DST's therapeutic success. Due to a large first-pass effect, animal research suggests that DST has an absolute bioavailability of 14–34 percent. Lipid-based drug delivery technologies, such as solid lipid nanoparticles (SLNs), can be utilised to circumvent hepatic first-pass metabolism and improve oral bioavailability. Methods: Submicron colloidal carriers with a size range of 50–1000 nm are known as SLNs. These are made from physiological lipids that have been distributed in water or an aqueous surfactant solution. By utilising intestinal lymphatic transport, DST can be easily loaded into SLNs to boost oral bioavailability. In a bioavailability research in rats, an ideal system was compared to that of DST suspension (SUS). Results: ATCC cell lines were used in an in vitro cytotoxicity research using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay technique, the percent inhibition was higher in SLN than in SUS. The pharmacokinetics of DST-SLNs in male Wistar rats following oral administration were investigated. When compared to a DST SUS, DST's bioavailability was improved by 2.28 times. Conclusion: The findings suggest that SLNs are a good lipid-based carrier system for increasing DST oral bioavailability.

Author(s) Details

A. A. Mohamed Yasir Arafath      
Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Salem, Tamil Nadu, India.

B. Jaykar
Vinayaka Mission’s Research Foundation (Deemed to be University), Salem, Tamil Nadu, India.

View Book :- https://stm.bookpi.org/CAPRD-V2/article/view/3962

An Overview on Nano Drug Delivery: Challenges and Its Safety Issues | Chapter 9 | Trends in Pharmaceutical Research and Development Vol. 5

 

The science and technology of precisely controlling the structure of matter at the molecular level is nanotechnology. It is the use of matter and its manipulation on a small scale. At this size, atoms and molecules behave differently and have a number of fascinating and unexpected uses. By manipulating matter on the nanometer length scale and exploiting novel phenomena and properties on that length scale, nanotechnology deals with the production of useful materials , devices and systems and systems. One approach to resolving the complexities of traditional drug delivery systems focused on the production and manufacture of nanostructures is nanotechnology. Various nanostructures used in drug delivery, their manufacturing techniques and nano drug delivery problems are studied. The present subject matter focuses primarily on the various nanostructures and their problems and potential safety concerns. Certain technology-related problems in terms of drug efficacy, Stability and enforcement by drug legislation. Better understanding and implementation of nanotechnology for successful drug delivery is expected to eventually increase the efficiency of drug treatment and patient enforcement. It will be difficult to deny the possible benefits of nanotechnology and to avoid the advancement of related science, because several different fields of research have already begun to break through. However, to ensure that the technology does not become too potentially dangerous, nanotechnology can be established using guidelines.

Author(s) Details

Dr. Bijay Kumar Sahoo
IMT Pharmacy College Puri, Sai Vihar, Gopalpur, Puri, 752004, Odisha, India.

Dr. Annada Prasad Mohapatra
IMT Pharmacy College Puri, Sai Vihar, Gopalpur, Puri, 752004, Odisha, India.

View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/303